A5029987430- Glioma Diagnosis and Treatment
- Neuroscience and Neural Engineering
- COVID-19 and healthcare impacts
- Meningioma and schwannoma management
- Neurosurgical Procedures and Complications
- Advanced Radiotherapy Techniques
- Brain Metastases and Treatment
- Intracerebral and Subarachnoid Hemorrhage Research
- Neurogenesis and neuroplasticity mechanisms
- Radiation Dose and Imaging
- Medical Imaging Techniques and Applications
- Bone Tissue Engineering Materials
- Head and Neck Surgical Oncology
- Cardiac, Anesthesia and Surgical Outcomes
- Molecular Communication and Nanonetworks
- Traumatic Brain Injury and Neurovascular Disturbances
- Nanoparticle-Based Drug Delivery
- Cerebrospinal fluid and hydrocephalus
- Esophageal and GI Pathology
- Tracheal and airway disorders
- Cancer, Hypoxia, and Metabolism
- Radiopharmaceutical Chemistry and Applications
- Cell Image Analysis Techniques
- Nanoplatforms for cancer theranostics
- Global Cancer Incidence and Screening
Aarhus University Hospital
2017-2024
Aarhus University
2019-2024
Aalborg University Hospital
2024
NIHR Birmingham Biomedical Research Centre
2021
University of Birmingham
2021
Yorkshire Cancer Research
2021
Urology Foundation
2021
Association for Cancer Surgery
2021
Tumor treating fields (TTFields) is a new modality used for the treatment of glioblastoma. It based on antineoplastic low-intensity electric induced by two pairs electrode arrays placed patient's scalp. The layout greatly impacts intensity (dose) TTFields in pathology. present study systematically characterizes impact array position distribution calculated realistic human head model using finite element methods. We investigate systematic rotations around central craniocaudal axis and...
Abstract Background Preclinical studies suggest that skull remodeling surgery (SR-surgery) increases the dose of tumor treating fields (TTFields) in glioblastoma (GBM) and prevents wasteful current shunting through skin. SR-surgery introduces minor defects to focus cancer-inhibiting currents toward increase treatment dose. This study aimed test safety feasibility this concept a phase I setting. Methods Fifteen adult patients with first recurrence GBM were treated personalized SR-surgery,...
Abstract Tumor-treating fields (TTFields) are currently a Category 1A treatment recommendation by the US National Comprehensive Cancer Center for patients with newly diagnosed glioblastoma. Although mechanism of action TTFields has been partly elucidated, tangible and standardized metrics lacking to assess antitumor dose effects treatment. This paper outlines evaluates current standards methodologies in estimation distribution measurement brain highlights most important principles governing...
Importance Intraventricular lavage has been proposed as a minimally invasive method to evacuate intraventricular hemorrhage. There is little evidence support its use. Objective To evaluate the safety and potential efficacy of treatment Design, Setting, Participants This single-blinded, controlled, investigator-initiated 1:1 randomized clinical trial was conducted at Aarhus University Hospital Odense in Denmark from January 13, 2022, November 24, 2022. Follow-up duration 90 days. The set...
Summary Glioblastomas (GBM) are renowned for their pronounced intratumoral heterogeneity, characterized by a diverse array of plastic cell types, which poses significant challenge to effective targeting and treatment [1]. Recent research has documented the presence neuronal-progenitor-like transcriptomic states GBM [2, 3], notably in leading edge tumor, where synaptic input from adjacent neurons drives disease proliferation [4]. However, conflicting observations regarding excitability,...
Abstract Background OptimalTTF-2 is a randomized, comparative, multi-center, investigator-initiated, interventional study aiming to test skull remodeling surgery in combination with Tumor Treating Fields therapy (TTFields) and best physicians choice medical oncological for first recurrence glioblastoma patients. phase 2 trial initiated November 2020. Skull consists of five burrholes, each 15 mm diameter, directly over the tumor resection cavity. Preclinical research indicates that this...
Skull-remodeling surgery has been proposed to enhance the dose of tumor treating fields in glioblastoma treatment. This abstract describes finite element methods used plan and evaluate treatment efficacy.
Abstract Background This study assessed the international variation in surgical neuro-oncology practice and 30-day outcomes of patients who had surgery for an intracranial tumor during COVID-19 pandemic. Methods We prospectively included adults aged ≥18 years underwent a malignant or benign across 55 hospitals from 26 countries. Each participating hospital recorded cases 3 consecutive months start categorized patients’ location by World Bank income groups (high [HIC], upper-middle [UMIC],...
Tumor treating fields (TTFields) are increasingly used as a fourth modality in glioblastoma therapy. TTFields alternating electrical fields, which inhibit cancer growth by disrupting mitotic processes. Optimization of efficacy requires thorough understanding distribution “dose” the brain. Here we provide simple guiding principles, facilitate intuitive such distributions and impact technology. Our results based on extensive field modeling. We estimated realistic human head model using finite...
Abstract BACKGROUND There are no standardized treatments for first recurrent glioblastoma (rGBM) and the prognosis in clinical trial population is approximately 6-9 months. Skull remodeling surgery (SR-surgery) aims to optimize Tumor Treating Fields therapy (TTFields) by surgically removing areas of low conductive skull thereby increasing electric field intensity directly into tumor. In silico work suggests SR-surgery increases ~30-100% OptimalTTF-1 (pilot trial) intervention safe with a...
Abstract Studies indicate that increasing the electric field intensity of Tumor Treating Fields therapy (TTFields) may prolong survival for glioblastoma (GBM) patients. Skull remodeling surgery (SR-surgery) aims to increase by 30-100% removing poorly conductive skull, and OptimalTTF-1 (pilot trial) concluded SR-surgery was safe with a median overall (mOS) 15.5 months first recurrence GBM (rGBM). OptimalTTF-2 is 1:1 randomized, comparative, multi-center, investigator-initiated, interventional...
Abstract Glioblastomas (GBM) are known for their significant intratumor heterogeneity, featuring a variety of plastic cell types that make effective treatment challenging. Recent studies have shown neuronal-progenitor-like transcriptomic states at the leading edge tumor receive synaptic input from nearby neurons, which drives disease proliferation. However, excitability GBM cells remains controversial, with observations ranging non-excitable to neuron-like excitability, complicating our...
We present a pre-specified interim analysis of an ongoing open-label, phase-1 IST (NCT02893137) testing safety/efficacy new rGBM treatment. The intervention combines personalized skull-remodeling (SR) surgery with TTFields and best-choice chemotherapy. SR-surgery involves minor craniectomy or burr-holes to enhance intensity focally in the tumor. Accrual began Dec 2016 (planned total 15 patients). Eligibility: Age > 18 years, first recurrence focal supratentorial GBM (RANO), KPS 70. Patients...
Tumor treating fields (TTFields) is an anti-cancer technology increasingly used for the treatment of glioblastoma. Recently, cranial burr holes have been experimentally to enhance intensity (dose) TTFields in underlying tumor region. In present study, we computational finite element methods systematically characterize impact hole position and transducer array layout on distribution calculated a realistic human head model. We investigated multitude positions layouts illustrate basic...
Abstract Introduction: Tumor treating fields (TTFields) is a new and effective treatment for glioblastoma. Two pairs of transducer arrays are placed on the scalp patient to deliver low intensity, alternating electric fields, which inhibit mitosis cancer growth. In present study, we investigated systematic variations in electrode array positions identify optimal layouts, induce highest tumor tissue. Method: The field distribution was calculated using finite element methods applied realistic...
Abstract Importance Intraventricular hemorrhage (IVH) is associated with high morbidity and mortality. A strong need exists for treatment advances. IRRAflow ® was recently introduced as a method minimally invasive, controlled, accelerated IVH wash-out. However, no current evidence supports this technology. Here, we present the first pivotal safety/efficacy evaluation in randomized controlled setting. Objective To evaluate safety efficacy of active hematoma irrigation using device compared...
We present an ongoing open label phase 1 investigator-sponsored trial (NCT02893137) testing safety/efficacy of a novel therapeutic concept for recurrent glioblastoma (GBM). The intervention combines best choice chemotherapy with tumor treating fields (TTFields) and personalized targeted skull remodeling surgery. objective surgery is to create paths, which facilitate electric current flow through into the region pathology. This may involve formation strategically placed minor craniectomies or...
Abstract Introduction Tumor Treating Fields (TTFields) is approved for the treatment of recurrent glioblastoma (rGBM). Skull remodeling surgery involves formation strategically placed craniectomies, burr holes or skull thinning, in order to facilitate electric current flow into tumor region. Preclinical studies have indicated that these procedures provide a marked and focal enhancement (~100%) TTFields intensity without significantly compromising patient safety. In this open-label phase 1...
Tumor treating fields (TTFields, Optune®) is an effective treatment for glioblastoma. The antimitotic effects of TTFields are induced by low-intensity, intermediate frequency (200 kHz) alternating electric fields, delivered through two pairs transducer arrays placed on the patient’s scalp. present study aimed to identify optimal array positions that highest field in tumor analyzing systematic variations layouts. distribution was computed using finite element methods with a realistic...
The non-invasive glioblastoma treatment, tumor treating fields (TTFields, Optune®), uses alternating electrical (200 kHz) to inhibit cancer cell division. TTFields are induced by two sequentially active pairs of transducer arrays placed on the patient’s scalp. Finite element (FE) methods used estimate field intensity TTFields. To date, calculations have focused entirely intensity, neglecting angle and exposure time that also influence efficacy. Based principal component analysis, this study...
We present a pre-specified interim analysis of an ongoing open-label, investigator-sponsored phase 1 trial (NCT02893137) testing safety/efficacy new rGBM treatment. The intervention combines personalized skull-remodeling (SR) surgery with TTFields and best-choice chemotherapy. SR-surgery involves minor craniectomy, burr-holes, and/or skull thinning to enhance intensity focally in the tumor. Accrual began Dec 2016 (planned total 15 patients). Eligibility: Age > 18 years, first recurrence...